Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained response

28 Dec 2017

Abstract excerpt

The widespread use of high-dose therapy and autologous stem cell transplantation (ASCT) as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma (MM) enabling long-term survival. We here analyze factors influencing survival in 865 newly diagnosed MM patients who underwent first-line ASCT at our center between 1993 and 2014. Relative survival and conditional survival...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29282899
DOI: 10.1002/cam4.1283

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of long‐term survival in multiple myeloma after first‐line autologous stem cell transplantation: impact of clinical risk factors and sustained responsePMID 29282899Read ↗

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantationSemantic proximity Read ↗

Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.Semantic proximity Read ↗

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group databaseSemantic proximity Read ↗

Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapySemantic proximity Read ↗

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantationSemantic proximity Read ↗

Establishing Measurable Residual Disease Trajectories for Patients on Treatment for Newly Diagnosed Multiple Myeloma as Benchmark for Deployment of T-cell Redirection TherapySemantic proximity Read ↗

Second Primary Malignancies Post Autologous Stem-cell Transplant in Multiple Myeloma from India – Knowing the UnknownSemantic proximity Read ↗

Current Review on High-Risk Multiple Myeloma.Semantic proximity Read ↗

Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or olderSemantic proximity Read ↗

Haematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-line Treatment With a Bortezomib-based RegimenSemantic proximity Read ↗

Management of high-risk Myeloma: an evidence-based review of treatment strategies.Semantic proximity Read ↗

The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.